share_log

PKU HealthCareLtd (SZSE:000788) Is Posting Promising Earnings But The Good News Doesn't Stop There

PKU HealthCareLtd (SZSE:000788) Is Posting Promising Earnings But The Good News Doesn't Stop There

北大醫療(SZSE:000788)發佈了令人振奮的收益,但好消息並不止於此
Simply Wall St ·  09/06 06:51

PKU HealthCare Corp.,Ltd.'s (SZSE:000788) recent earnings report didn't offer any surprises, with the shares unchanged over the last week. We did some digging, and we think that investors are missing some encouraging factors in the underlying numbers.

北京大學醫藥保健股份有限公司(SZSE:000788)最近的業績沒有提供任何意外,股價在過去一週保持不變。經過一番調查,我們認爲投資者對底層數據中的一些鼓舞人心的因素存在誤解。

big
SZSE:000788 Earnings and Revenue History September 5th 2024
SZSE:000788收入歷史和財務數據 2024年9月5日

Zooming In On PKU HealthCareLtd's Earnings

聚焦PKU HealthCareLtd的盈利情況

One key financial ratio used to measure how well a company converts its profit to free cash flow (FCF) is the accrual ratio. To get the accrual ratio we first subtract FCF from profit for a period, and then divide that number by the average operating assets for the period. This ratio tells us how much of a company's profit is not backed by free cashflow.

用於衡量公司將其盈利轉換成自由現金流(FCF)的一個關鍵財務比率是應計比率。爲了得出應計比率,我們首先從一個期間的利潤中減去FCF,然後將該數字除以期間的平均經營資產。這個比率告訴我們公司利潤有多少不受自由現金流支持。

Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. To quote a 2014 paper by Lewellen and Resutek, "firms with higher accruals tend to be less profitable in the future".

因此,當公司的應計比率爲負時,實際上是一件好事,但如果其應計比率爲正,則是一件壞事。雖然應計比率爲零以上的事情無關緊要,但我們認爲當公司的應計比率相對較高時,值得注意。引用Lewellen和Resutek在2014年發表的一篇論文:「應計越高的公司未來利潤率越低」。

For the year to June 2024, PKU HealthCareLtd had an accrual ratio of -0.12. That implies it has good cash conversion, and implies that its free cash flow solidly exceeded its profit last year. In fact, it had free cash flow of CN¥238m in the last year, which was a lot more than its statutory profit of CN¥99.4m. PKU HealthCareLtd shareholders are no doubt pleased that free cash flow improved over the last twelve months. However, that's not all there is to consider. The accrual ratio is reflecting the impact of unusual items on statutory profit, at least in part.

對於截至2024年6月的一年,北京大學醫藥保健股份有限公司的應計比率爲-0.12。這意味着它具有良好的現金轉換能力,並且表明其自由現金流去年明顯超過其利潤。實際上,去年它的自由現金流爲23800萬元人民幣,遠遠超過其法定利潤9940萬元人民幣。北京大學醫藥保健股份有限公司的股東無疑對過去十二個月的自由現金流改善感到滿意。但這並不是唯一需要考慮的因素,應計比率反映了異常項目對法定利潤的影響,至少部分如此。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of PKU HealthCareLtd.

注:我們始終建議投資者檢查資產負債表的強度。點擊此處查看我們對北京大學醫藥保健股份有限公司的資產負債表分析。

The Impact Of Unusual Items On Profit

除了稀釋之外,還應該注意的是,萬集科技在過去12個月中因不尋常項目獲得了價值人民幣3.5萬元的利潤。雖然我們希望看到利潤增加,但當這些不尋常項目對利潤做出重大貢獻時,我們會更加謹慎。我們對全球大部分上市公司的數據進行了分析,發現不尋常項目往往是一次性的。這正如我們所期望的那樣,因爲這些提升被描述爲"不尋常"。相對於其利潤而言,萬集科技在2021年12月前的不尋常項目貢獻大。因此,我們可以推斷出,這些不尋常項目正在使其財務利潤顯著增強。

PKU HealthCareLtd's profit was reduced by unusual items worth CN¥17m in the last twelve months, and this helped it produce high cash conversion, as reflected by its unusual items. In a scenario where those unusual items included non-cash charges, we'd expect to see a strong accrual ratio, which is exactly what has happened in this case. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And, after all, that's exactly what the accounting terminology implies. If PKU HealthCareLtd doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

北京大學醫療保健有限公司在過去十二個月中由於飛凡項目損失了1700萬元,這有助於它產生高的現金轉化率。在那些飛凡項目包括非現金費用的情況下,我們預期會看到較高的應計比率,而在這個案例中確實是如此。看到飛凡項目導致公司損失利潤確實不太好,但好處是事情可能會比預期更快地好轉。當我們分析了全球大部分上市公司時,發現重大的飛凡項目通常不會重複發生。而且,歸根結底,這正是會計術語所暗示的。如果北京大學醫療保健有限公司不再出現這些異常費用,其他一切不變的情況下,我們預計其利潤將在未來一年內增加。

Our Take On PKU HealthCareLtd's Profit Performance

我們對北京大學醫療保健有限公司的利潤表現的看法

Considering both PKU HealthCareLtd's accrual ratio and its unusual items, we think its statutory earnings are unlikely to exaggerate the company's underlying earnings power. Looking at all these factors, we'd say that PKU HealthCareLtd's underlying earnings power is at least as good as the statutory numbers would make it seem. While earnings are important, another area to consider is the balance sheet. If you're interested we have a graphic representation of PKU HealthCareLtd's balance sheet.

考慮到北京大學醫療保健有限公司的應計比率和異常項目,我們認爲其法定盈利不太可能誇大公司的基本盈利能力。綜合考慮所有這些因素,我們可以說,北京大學醫療保健有限公司的基本盈利能力至少與法定數據看起來一樣好。雖然盈利很重要,但另一個要考慮的領域是資產負債表。如果您有興趣,我們有一張關於北京大學醫療保健有限公司資產負債表的圖像代表。

Our examination of PKU HealthCareLtd has focussed on certain factors that can make its earnings look better than they are. And it has passed with flying colours. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

我們對北京大學醫療保健有限公司的審查主要關注了一些可以讓其利潤看起來比實際情況更好的因素。而且它已經通過了。但是還有很多其他方法可以了解一家公司的情況。有些人認爲高股本回報率是一個優質企業的良好標誌。雖然這可能需要您自己做一些研究,但您可能會發現這份免費的高股本回報率公司收藏或者持有重要內部股權的股票清單對您有所幫助。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論